Clinical Trials

Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)

Cancer Type

Solid Tumor

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

John Sarantopoulos MD

For more information about this study
View Details

About This Study

Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors